Friday, November 6, 2026

Nikkei 225 Went Up By Over 9% In The Last 21 Sessions

ViaNews Editorial Team

October 10, 2024

Nikkei 225 Went Up By Over 9% In The Last 21 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 9.01% for the last 21 sessions. At 21:08 EST on Wednesday, 9 October, Nikkei 225 (N225) is $39,478.96.

About Nikkei 225's yearly highs and lows, it's 29.28% up from its 52-week low and 6.95% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was 0.47%, 0.44%, and 1.75%, respectively.

Nikkei 225's highest amplitude of average volatility was 0.98% (last week), 1.67% (last month), and 1.75% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to Zacks on Tuesday, 8 October, "View all Key Company Metrics for JPMorgan Chase & Co. here>>>Shares of JPMorgan Chase & Co. have demonstrated returns of -2.7% over the past month compared to the Zacks S&P 500 composite's +5.4% change. "
  • According to Zacks on Tuesday, 8 October, "Tuesday, October 8th, 2024Pre-market futures look to build back from the sell-off in Monday's session, which saw the Dow slide -0.94%, the S&P 500 -0.96% and the Nasdaq -1.18%. ", "Of course, we've already begun to have S&P 500 companies report for Q3, including Pepsi (PEP Quick QuotePEP - Free Report) this morning (it beat by a penny) and Delta Air Lines (DAL Quick QuoteDAL - Free Report) on Thursday. "
  • According to FXStreet on Tuesday, 8 October, "The S&P 500 continues to trade within a consolidation, as we can see on the daily chart.", "I opened a speculative short position in the S&P 500 futures contract on September 16."
  • According to Zacks on Tuesday, 8 October, "View all Key Company Metrics for The Bank of New York Mellon here>>>The Bank of New York Mellon shares have witnessed a change of +7% in the past month, in contrast to the Zacks S&P 500 composite's +5.4% move. "

More news about Nikkei 225 (N225).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com